Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
Abstract Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized therapeutic options by reactivating the host immune system. However, the efficacy varies, and only a small portion of patients develop sustained antitumor responses. Hence, illustrating novel strategies that impr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01746-6 |
| _version_ | 1797865380653301760 |
|---|---|
| author | Xianyong Zhou Chen Li Tong Chen Wenhao Li Xiaolong Wang Qifeng Yang |
| author_facet | Xianyong Zhou Chen Li Tong Chen Wenhao Li Xiaolong Wang Qifeng Yang |
| author_sort | Xianyong Zhou |
| collection | DOAJ |
| description | Abstract Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized therapeutic options by reactivating the host immune system. However, the efficacy varies, and only a small portion of patients develop sustained antitumor responses. Hence, illustrating novel strategies that improve the clinical outcome of immune checkpoint therapy is urgently needed. N6-methyladenosine (m6A) has been proved to be an efficient and dynamic posttranscriptional modification process. It is involved in numerous RNA processing, such as splicing, trafficking, translation and degradation. Compelling evidence emphasizes the paramount role of m6A modification in the regulation of immune response. These findings may provide a foundation for the rational combination of targeting m6A modification and immune checkpoints in cancer treatment. In the present review, we summarize the current landscape of m6A modification in RNA biology, and highlight the latest findings on the complex mechanisms by which m6A modification governs immune checkpoint molecules. Furthermore, given the critical role of m6A modification in antitumor immunity, we discuss the clinical significance of targeting m6A modification to improve the efficacy of immune checkpoint therapy for cancer control. |
| first_indexed | 2024-04-09T23:07:04Z |
| format | Article |
| id | doaj.art-1665f21b92d34145acd79c731cf478f6 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-09T23:07:04Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-1665f21b92d34145acd79c731cf478f62023-03-22T10:35:18ZengBMCMolecular Cancer1476-45982023-02-0122112010.1186/s12943-023-01746-6Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapyXianyong Zhou0Chen Li1Tong Chen2Wenhao Li3Xiaolong Wang4Qifeng Yang5Department of Breast Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Breast Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Breast Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Breast Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Breast Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong UniversityDepartment of Breast Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong UniversityAbstract Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized therapeutic options by reactivating the host immune system. However, the efficacy varies, and only a small portion of patients develop sustained antitumor responses. Hence, illustrating novel strategies that improve the clinical outcome of immune checkpoint therapy is urgently needed. N6-methyladenosine (m6A) has been proved to be an efficient and dynamic posttranscriptional modification process. It is involved in numerous RNA processing, such as splicing, trafficking, translation and degradation. Compelling evidence emphasizes the paramount role of m6A modification in the regulation of immune response. These findings may provide a foundation for the rational combination of targeting m6A modification and immune checkpoints in cancer treatment. In the present review, we summarize the current landscape of m6A modification in RNA biology, and highlight the latest findings on the complex mechanisms by which m6A modification governs immune checkpoint molecules. Furthermore, given the critical role of m6A modification in antitumor immunity, we discuss the clinical significance of targeting m6A modification to improve the efficacy of immune checkpoint therapy for cancer control.https://doi.org/10.1186/s12943-023-01746-6Cancer immunotherapyImmune checkpointEpigeneticsN6-methyladenosinem6A regulators |
| spellingShingle | Xianyong Zhou Chen Li Tong Chen Wenhao Li Xiaolong Wang Qifeng Yang Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy Molecular Cancer Cancer immunotherapy Immune checkpoint Epigenetics N6-methyladenosine m6A regulators |
| title | Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy |
| title_full | Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy |
| title_fullStr | Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy |
| title_full_unstemmed | Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy |
| title_short | Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy |
| title_sort | targeting rna n6 methyladenosine to synergize with immune checkpoint therapy |
| topic | Cancer immunotherapy Immune checkpoint Epigenetics N6-methyladenosine m6A regulators |
| url | https://doi.org/10.1186/s12943-023-01746-6 |
| work_keys_str_mv | AT xianyongzhou targetingrnan6methyladenosinetosynergizewithimmunecheckpointtherapy AT chenli targetingrnan6methyladenosinetosynergizewithimmunecheckpointtherapy AT tongchen targetingrnan6methyladenosinetosynergizewithimmunecheckpointtherapy AT wenhaoli targetingrnan6methyladenosinetosynergizewithimmunecheckpointtherapy AT xiaolongwang targetingrnan6methyladenosinetosynergizewithimmunecheckpointtherapy AT qifengyang targetingrnan6methyladenosinetosynergizewithimmunecheckpointtherapy |